Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma Clinical Trial

Official title:

Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05432518
• Other study ID #: GBM-2022
• Status: Recruiting
• Phase: Early Phase 1
• Start date: June 27, 2023
• Est. completion date: December 1, 2027

Study information

• Verified date: May 2024
• Source: AHS Cancer Control Alberta
• Contact: Paula de Robles, MD
• Phone: 403-944-8386
• Email: paula.derobles[@]albertahealthservices.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This will be a single-arm open-label prospective pilot feasibility trial recruiting 10 adult patients with recurrent glioblastoma who are assigned to receive the personalized study treatment based on the genetic profile of their recurrent GBM tumor resected at the time of surgery. It will be aimed to gather preliminary information on the study intervention and the feasibility of conducting a full-scale trial.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 1, 2027
• Est. primary completion date: July 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Study participant has provided informed consent prior to initiation of any study specific activities/procedures.

2. Adult participants, male and female, aged =18 who have a pathologically confirmed IDH-wild type glioblastoma, with first or second progression of the tumor, after initial treatment with radiation therapy and temozolomide.

3. Recurrence is amenable to resection.

4. Performance status: ECOG =2.

5. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.

6. Patients of childbearing potential must adhere to the contraception requirement from screening throughout the study period up to 180 days after the last dose of study intervention. Women/men of childbearing potential must have agreed to use two highly effective contraceptive methods. In addition to routine contraceptive methods such as condom use, oral contraceptive, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.

Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.

7. Able to undergo brain MRIs.

8. Females must not be breastfeeding, throughout the study period up to 180 days after the last dose of study intervention.

9. Male patients should agree to not donate sperm during the study for at least 6 months until discontinuation of study drug.

Exclusion Criteria:

1. Patients with history of abnormal left ventricular ejection fraction (LVEF= 45%).

2. Pregnant, breast-feeding, unwilling/unable to comply with contraception requirements.

3. Patients unable to consent.

4. Abnormal (grade =2 CTCAE, version 5.0) laboratory values for hematology, renal, and liver function including:

1. Hemoglobin <10,

2. Neutrophils <1.5,

3. Platelets <75,

4. ALT/AST >3x ULN,

5. Bilirubin >1.5 x ULN,

6. eGFR <60

5. Patients with significant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption or severe diarrhea of any etiology) must be excluded from the clinical trial (Afatanib is not recommended in this patient population).

6. Patients with a history of ILD (interstitial lung disease) must be excluded.

7. Patients with severe hepatic impairment (Child Pugh C).

8. A significantly abnormal ECG (baseline QTcF interval > 450 msec).

9. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.

10. Patients with known pre-existing pleural effusion.

11. Active hepatitis B or C infection and/or known history of HIV infection.

12. Has known psychiatric or substance abuse disorders that would interfere with compliance with the requirements of the trial.

13. Subject will not be available for protocol-required study visits or procedures, to the best of the subject's and investigator's knowledge.

14. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks from the date of signing the informed consent form.

15. Patients who are hypersensitive to any ingredients in the formulation of the study drugs or their excipients.

16. Patients receiving active treatment for a different cancer.

17. If recent bacterial infection, patients need to have completed antibiotic course prior to commencing study drug.

18. If recent COVID-19 infection, patients must have recovered from it prior to commencing study drug.

19. Patients on strong CYP3A/p-gp inducers (for example, carbamazepine and phenytoin).

Related Conditions & MeSH terms

• Glioblastoma
• Recurrence
• Recurrent Disease
• Recurrent Glioblastoma

Intervention

Drug:
• Afatinib
Afatinib will be administered orally at a dose of 40 mg daily in patients with EGFR amplification.
• Dasatinib
Dasatinib will be administered orally at a dose of 100 mg once daily in patients with PDGFR amplification.
• Palbociclib
Palbociclib will be administered orally at a dose of 125 mg once daily in patients with CDK4 and CDK6 amplification.
• Everolimus
Everolimus will be administered orally at a dose of 10 mg daily in patients with PI3K/PTEN/mTOR activated pathways.
• Olaparib
Olaparib will be administered orally at a dose of 300 mg twice daily in patients with TP53 mutation.

Locations

Country	Name	City	State
Canada	Tom Baker Cancer Centre	Calgary	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
AHS Cancer Control Alberta	Tom Baker Cancer Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Genomic and expression profiling	Number of patients for whom we were able to have genomic and expression profiling on their tissue samples and organoids	From date of initial consent to participate to end of follow up period (24 months)
Other	Organoid drug response	Number of patients for whom we can determine organoid drug response to study drugs	From date of initial consent to participate to end of follow up period (24 months)
Other	Correlation of genomic and expression profiling of tissue and organoid with the organoid's best drug response	Number of patients for whom the genomic and expression profiling of their tissue and organoid directly correlates to the organoid's best drug response	From date of initial consent to participate to end of follow up period (24 months)
Primary	Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor	Percentage of patients, interested in participating, consented and detected with target mutations and completed the treatment with one of the 5 study drugs	From date of initial consent to participate to the end of follow up period (24 months)
Secondary	Overall survival (OS)	OS is calculated as the period from the day of starting administration of the study drug to the day of death from any cause.	From date of study drug administration until date of death from any cause (approximately 24 months)
Secondary	Progression free survival (PFS)	PFS is calculated as the period from the day of starting administration of the study drug to the date that disease progression is confirmed by radiographic assessment and RANO criteria.	From date of study drug administration until date of radiographic confirmed progression (approximately 2 years)
Secondary	Quality of Life (QoL) EORTC QLQ-C30	The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.	Baseline until the end of treatment
Secondary	Quality of Life (QoL) EORTC QLQ BN-20	Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment. EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.; The scores across all time points were averaged to obtain the mean.	Baseline until the end of treatment